TrialBlood advances2025

Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.

Annette von Drygalski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.